317 related articles for article (PubMed ID: 38123873)
1. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
2. Endostatin specifically targets both tumor blood vessels and lymphatic vessels.
Zhuo W; Chen Y; Song X; Luo Y
Front Med; 2011 Dec; 5(4):336-40. PubMed ID: 22198745
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
4. Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies.
Tee D; DiStefano J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):15-24. PubMed ID: 14586644
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
Dass CR; Tran TM; Choong PF
J Dent Res; 2007 Oct; 86(10):927-36. PubMed ID: 17890668
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.
Tan H; Mu G; Zhu W; Liu J; Wang F
Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643
[TBL] [Abstract][Full Text] [Related]
7. Endostatin and anastellin inhibit distinct aspects of the angiogenic process.
Neskey DM; Ambesi A; Pumiglia KM; McKeown-Longo PJ
J Exp Clin Cancer Res; 2008 Nov; 27(1):61. PubMed ID: 18983664
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
9. Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.
Li ZY; Zhu F; Hu JL; Peng G; Chen J; Zhang S; Chen X; Zhang RG; Chen LJ; Liu P; Luo M; Sun ZH; Ren JH; Huang LL; Wu G
Tumour Biol; 2011 Aug; 32(4):677-87. PubMed ID: 21442281
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.
Wang H; Yang Z; Gu J
Mol Cancer Ther; 2014 Nov; 13(11):2674-87. PubMed ID: 25127900
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
14. Role of angiogenesis in tumor growth and metastasis.
Folkman J
Semin Oncol; 2002 Dec; 29(6 Suppl 16):15-8. PubMed ID: 12516034
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer.
Liu ZJ; Wang J; Wei XY; Chen P; Wang LC; Lin L; Sun BC; Li K
J Cancer Res Clin Oncol; 2012 Jun; 138(6):927-37. PubMed ID: 22331237
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Macpherson GR; Ng SS; Forbes SL; Melillo G; Karpova T; McNally J; Conrads TP; Veenstra TD; Martinez A; Cuttitta F; Price DK; Figg WD
Mol Cancer Ther; 2003 Sep; 2(9):845-54. PubMed ID: 14555703
[TBL] [Abstract][Full Text] [Related]
17. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights.
Chamani R; Asghari SM; Alizadeh AM; Eskandari S; Mansouri K; Khodarahmi R; Taghdir M; Heidari Z; Gorji A; Aliakbar A; Ranjbar B; Khajeh K
Vascul Pharmacol; 2015 Sep; 72():73-82. PubMed ID: 26187352
[TBL] [Abstract][Full Text] [Related]
18. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
19. Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2-mediated angiogenesis.
Pan F; Yang W; Li W; Yang XY; Liu S; Li X; Zhao X; Ding H; Qin L; Pan Y
Tumour Biol; 2017 Jul; 39(7):1010428317708547. PubMed ID: 28714365
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
